Used in the treatment of eosinophilic gastrointestinal disorders, this antibody targets Siglec-8 on eosinophils and mast cells, inducing cell death and reducing inflammation. It shows promise in conditions like eosinophilic gastritis and esophagitis by decreasing tissue eosinophil counts and improving symptoms. Currently under clinical investigation, it offers a biologic approach for patients unresponsive to standard therapies.